UCB SA

ENXTBR:UCB Rapport sur les actions

Capitalisation boursière : €47.9b

UCB Gestion

Gestion contrôle des critères 2/4

Nous ne disposons actuellement pas d’informations suffisantes sur le PDG.

Informations clés

Jean-Christophe Tellier

Directeur général

€12.4m

Rémunération totale

Pourcentage du salaire du PDG11.26%
Durée du mandat du directeur général11.4yrs
Propriété du PDGn/a
Durée moyenne d'occupation des postes de direction5.9yrs
Durée moyenne du mandat des membres du conseil d'administration8.7yrs

Mises à jour récentes de la gestion

Recent updates

Mise à jour du récit • May 15

UCB: Epilepsy Blockbusters And Neuroscience Pipeline Will Drive Future Upside Potential

Analysts have nudged their average price target for UCB higher, with fair value moving from €284.65 to about €288.21 as they factor in updated assumptions on discount rate, revenue growth, profit margins, and future P/E, supported by recent target hikes and fresh Outperform ratings on the stock. Analyst Commentary Recent research points to a split but constructive view on UCB, with several firms adjusting ratings and targets as they reassess the stock's risk and reward profile.
Mise à jour du récit • Apr 30

UCB: Epilepsy Portfolio Execution To Drive Future Earnings Power Upside

The analyst fair value estimate for UCB has shifted from €310 to €340, reflecting updated assumptions on revenue growth, higher projected profit margins, a slightly adjusted discount rate, a revised future P/E, and recent Street research in which analysts highlight UCB's epilepsy portfolio and reset price targets in the €300 to €340 range. Analyst Commentary Recent Street research on UCB has been mixed, with some caution on near-term risk and reward but also clear pockets of optimism tied to its neuroscience and epilepsy franchises.
Mise à jour du récit • Apr 16

UCB: Epilepsy And Neuroscience Execution Will Shape Balanced Risk Reward Profile

Analysts have adjusted the UCB price target toward €285, reflecting a blend of more cautious views that see risk and reward as balanced around €260 and more optimistic calls pointing toward €304 to €340, supported by expectations for its epilepsy portfolio and broader neuroscience exposure. Analyst Commentary Bullish Takeaways Bullish analysts see upside toward €304 to €340, suggesting that current pricing does not fully reflect expectations around the epilepsy portfolio and broader neuroscience pipeline.
Mise à jour du récit • Apr 01

UCB: Epilepsy Franchise And Dermatology Data Will Shape Future Risk Reward Balance

Narrative Update on UCB The analyst price target for UCB has been adjusted slightly lower to about €285. This reflects a blend of more cautious views that see a balanced risk and reward at current levels, and more optimistic targets that highlight UCB's epilepsy portfolio and recent upward revisions from several banks.
Mise à jour du récit • Mar 18

UCB: Epilepsy And Psoriatic Arthritis Execution Will Shape Future Risk Reward Balance

The updated analyst price target for UCB moves to €284.85 from €275.74. This reflects a mix of more conservative revenue growth assumptions, higher expected profit margins, and a lower future P/E multiple, in line with recent research that balances enthusiasm around epilepsy assets with a more measured view on risk and reward.
Mise à jour du récit • Mar 04

UCB: Epilepsy Franchise Expectations Will Eventually Strain Current Share Price

We are lifting our fair value estimate for UCB from €173.07 to €209.22, reflecting higher assumed revenue growth and profit margins as analysts highlight a stronger outlook for the epilepsy franchise and raise price targets into the €300+ range. Analyst Commentary Recent Street research on UCB has centered on the epilepsy franchise and the broader neuroscience portfolio, with several firms updating their views and price targets.
Mise à jour du récit • Feb 18

UCB: Epilepsy Pipeline Progress And Execution Will Shape Future Upside Balance

Our Analyst Price Target for UCB has moved higher from €261.42 to €275.74, reflecting analysts' updated assumptions on revenue growth, profitability and P/E in light of recent Street target lifts to around €304 to €310. Analyst Commentary Recent Street research on UCB has centered on higher price targets, with bullish analysts adjusting their views to reflect updated assumptions on revenue, profitability and P/E.
Mise à jour du récit • Feb 04

UCB: Future Earnings Power To Reflect Rare Disease And Epilepsy Execution

Analysts have raised their price target on UCB to €310 from €270, citing updated assumptions for revenue growth, profit margins and a slightly lower future P/E multiple as the main drivers of the change. Analyst Commentary Recent commentary from bullish analysts has centered on higher valuation support for UCB, with the new €310 price target used as a reference point for what they see as stronger execution and earnings potential than previously modeled.
Mise à jour du récit • Jan 21

UCB: Late-Stage Pipeline And Margin Execution Will Shape Balanced Upside Potential

Analysts raised their price target on UCB to €310 from €270, citing updated expectations for slightly stronger revenue growth, improved profit margins, and a modestly lower future P/E multiple. Analyst Commentary Bullish Takeaways Bullish analysts point to the higher €310 target as a sign that they see current valuation as not fully reflecting updated revenue and margin expectations.
Mise à jour du récit • Jan 07

UCB: Raising Future Fair Value On Strengthening Rare Disease And Epilepsy Franchise

Analysts have raised their fair value estimate for UCB from €255 to €310, citing recent price target increases from the Street and updated assumptions on revenue growth, profit margins and future P/E levels. Analyst Commentary Bullish analysts have recently adjusted their views on UCB, with fresh price targets that now cluster around €290 to €310.
Mise à jour du récit • Dec 18

UCB: Expanding Late-Stage Pipeline And New Launches Will Drive Future Upside

UCB's analyst price target has been raised from EUR 258.33 to EUR 264.67 as analysts factor in slightly stronger revenue growth expectations, despite a modestly lower projected profit margin and only a small uptick in future valuation multiples. Analyst Commentary Recent price target increases signal that bullish analysts see a more attractive risk reward profile for UCB, driven by improving growth visibility and confidence in execution.
Mise à jour du récit • Dec 04

UCB: Pipeline Execution And New Launches Will Support Balanced Future Upside Potential

UCB's fair value estimate has been nudged higher to approximately EUR 258 from EUR 257, reflecting analysts' upward revisions to price targets, with recent moves to EUR 240, EUR 285 and EUR 290. These changes highlight confidence in the company's earnings trajectory despite slightly softer margin and growth assumptions.
Mise à jour du récit • Nov 20

UCB: Recent Pipeline Advances And Margin Strength Will Drive Share Price Higher

Analysts have slightly raised their fair value estimate for UCB to €256.67. They cite recent upward revisions to price targets, supported by continued expectations for stable profit margins and healthy revenue growth.
Article d’analyse • Nov 11

UCB (EBR:UCB) Could Easily Take On More Debt

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Mise à jour du récit • Nov 06

UCB: Strong Profit Margins And Momentum Will Drive Shares Higher

UCB's fair value estimate has increased by approximately EUR 4.50, as analysts highlight robust performance and upward revisions to price targets. This follows renewed confidence in the company’s profit margin outlook.
Mise à jour du récit • Oct 22

Analysts Raise UCB Price Targets Amid Positive Sector Outlook and Improved Growth Forecasts

UCB's analyst price target has been raised from €240.28 to €251.11, as analysts cite upward revisions to revenue growth forecasts along with an improved sector outlook. Analyst Commentary Recent analyst actions reflect a strongly positive sentiment toward UCB's outlook, as multiple firms have revised their price targets upward and maintained favorable ratings.
Article d’analyse • Oct 14

Market Participants Recognise UCB SA's (EBR:UCB) Earnings Pushing Shares 25% Higher

UCB SA ( EBR:UCB ) shares have continued their recent momentum with a 25% gain in the last month alone. Looking back a...
Mise à jour du récit • Oct 08

Aging Populations And Emerging Markets Will Unlock Opportunity

UCB's analyst price target has been increased from €229.06 to €240.28. This change reflects improved revenue growth expectations and profit margins highlighted by recent analyst updates.
Mise à jour du récit • Sep 24

Aging Populations And Emerging Markets Will Unlock Opportunity

The slight increase in UCB’s consensus price target to €229.06 reflects improved revenue growth forecasts, while profit margin expectations remain stable. What's in the News Three-year data from BE HEARD trials show sustained efficacy and quality of life improvements with BIMZELX® in moderate-to-severe hidradenitis suppurativa, with better outcomes linked to earlier treatment.
Mise à jour du récit • Aug 27

Aging Populations And Emerging Markets Will Unlock Opportunity

Analysts have raised their price target for UCB to €223.17, citing robust fundamentals, resilient earnings growth, and improved confidence in management despite recent share price weakness. Analyst Commentary Recent share price pullback seen as disconnected from underlying business strength.
Article d’analyse • Jul 17

UCB SA (EBR:UCB) Not Lagging Market On Growth Or Pricing

When close to half the companies in Belgium have price-to-earnings ratios (or "P/E's") below 14x, you may consider UCB...
User avatar
Nouveau récit • Mar 02

BIMZELX's Successful Launch Will Expand Future Market Opportunities In Dermatology And Rheumatology

UCB's new product launches and high R&D success rate are driving anticipated revenue and margin growth across global markets.

Analyse de la rémunération des PDG

Comment la rémunération de Jean-Christophe Tellier a-t-elle évolué par rapport aux bénéfices de UCB?
DateRémunération totaleSalaireBénéfices de l'entreprise
Dec 31 2025€12m€1m

€2b

Sep 30 2025n/an/a

€1b

Jun 30 2025n/an/a

€1b

Mar 31 2025n/an/a

€1b

Dec 31 2024€7m€1m

€1b

Sep 30 2024n/an/a

€653m

Jun 30 2024n/an/a

€240m

Mar 31 2024n/an/a

€292m

Dec 31 2023€7m€1m

€343m

Jun 30 2023n/an/a

€332m

Mar 31 2023n/an/a

€376m

Dec 31 2022€6m€1m

€420m

Jun 30 2022n/an/a

€887m

Mar 31 2022n/an/a

€971m

Dec 31 2021€6m€1m

€1b

Sep 30 2021n/an/a

€996m

Jun 30 2021n/an/a

€936m

Mar 31 2021n/an/a

€834m

Dec 31 2020€7m€1m

€732m

Jun 30 2020n/an/a

€743m

Mar 31 2020n/an/a

€767m

Dec 31 2019€87kn/a

€790m

Rémunération vs marché: La rémunération totale de Jean-Christophe ($USD 14.51M ) est supérieure à la moyenne des entreprises de taille similaire sur le marché Belgian ($USD 2.87M ).

Rémunération et revenus: La rémunération de Jean-Christophe a augmenté de plus de 20 % au cours de l'année écoulée.

PDG

Jean-Christophe Tellier (67 yo)

11.4yrs
Titularisation
€12,434,367
Compensation

Dr. Jean-Christophe Tellier is Chief Executive Officer of UCB Ventures S.A. Dr. Jean-Christophe Tellier is CEO & Executive Director of UCB SA from July 01, 2020. Dr. Tellier served as Executive Vice Presid...

Équipe de direction

NomPositionTitularisationCompensationPropriété
Jean-Christophe Tellier
CEO & Executive Director11.4yrs€12.43mpas de données
Sandrine Dufour
Executive VP & CFO5.9yrspas de donnéespas de données
Alistair Henry
Executive VP & Chief Scientific Officer2.1yrspas de donnéespas de données
Denelle J. Johnson
Executive VP & General Counsel3.2yrspas de donnéespas de données
Jean-Luc Fleurial
Executive VP & Chief Human Resources Officer6.3yrspas de donnéespas de données
Emmanuel Caeymaex
Executive Vice President of Patient Evidence11.3yrspas de donnéespas de données
Kirsten Lund-Jurgensen
Executive Vice President of Patient Supply2.4yrspas de donnéespas de données
Fiona du Monceau
Executive VP of Patient Impact & Chief Commercial Officer2.2yrspas de donnéespas de données
Caroline Vancoillie
Chief Accounting Officer & Head of Group Finance13.3yrspas de donnéespas de données
Gwendoline Ornigg
Head of Global Corporate Communicationno datapas de donnéespas de données
Veronique Toully
Head of Sustainabilityno datapas de donnéespas de données
Martin Citron
VP & Head of Neuroscience TA New Medicinesno datapas de donnéespas de données
5.9yrs
Durée moyenne de l'emploi
59.5yo
Âge moyen

Gestion expérimentée: L'équipe dirigeante de UCB est chevronnée et expérimentée (5.9 années d'ancienneté moyenne).

Membres du conseil d'administration

NomPositionTitularisationCompensationPropriété
Jean-Christophe Tellier
CEO & Executive Director12.2yrs€12.43mpas de données
Gerhard Mayr
Honorary Chairmanno data€70.00kpas de données
Mark Eyskens
Honorary Chairman21.4yrs€15.50kpas de données
Daniel Janssen
Honorary Deputy Chairmanno data€28.50kpas de données
Georges Jacobs Hagen
Honorary Chairmanno data€30.00kpas de données
Diégo du de Bergendal
Honorary Chairman5.2yrs€87.50kpas de données
Karel Boone
Honorary Chairmanno data€49.00kpas de données
Judy L. Brown
Independent Directorless than a yearpas de donnéespas de données
Jonathan Peacock
Independent Chair of the Board5.2yrs€438.33kpas de données
Charles-Antoine Janssen
Vice-Chair of the Board14.2yrs€192.33kpas de données
Nefertiti Greene
Independent Director2.4yrs€197.33kpas de données
Jonkheer van Rijckevorsel
Director12.2yrs€157.83kpas de données
8.7yrs
Durée moyenne de l'emploi
68yo
Âge moyen

Conseil d'administration expérimenté: Les membres du conseil d'administration de UCB sont considérés comme expérimentés (ancienneté moyenne 8.7 ans).

Analyse de l'entreprise et données financières

DonnéesDernière mise à jour (heure UTC)
Analyse de l'entreprise2026/06/01 10:27
Cours de l'action en fin de journée2026/05/29 00:00
Les revenus2025/12/31
Revenus annuels2025/12/31

Sources de données

Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.

PaquetDonnéesCadre temporelExemple de source américaine *
Finances de l'entreprise10 ans
  • Compte de résultat
  • Tableau des flux de trésorerie
  • Bilan
Estimations consensuelles des analystes+3 ans
  • Prévisions financières
  • Objectifs de prix des analystes
Prix du marché30 ans
  • Cours des actions
  • Dividendes, scissions et actions
Propriété10 ans
  • Actionnaires principaux
  • Délits d'initiés
Gestion10 ans
  • L'équipe dirigeante
  • Conseil d'administration
Principaux développements10 ans
  • Annonces de l'entreprise

* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.

Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.

Modèle d'analyse et flocon de neige

Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github; nous proposons également des guides expliquant comment utiliser nos rapports et des tutoriels sur Youtube.

Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.

Indicateurs de l'industrie et du secteur

Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.

Sources des analystes

UCB SA est couverte par 40 analystes. 16 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.

AnalysteInstitution
Charles PitmanBarclays
Charles PitmanBarclays
Brian BourdotBarclays